Dr. Reddy's Laboratories Ltd.
Overview
Dr. Reddy's Laboratories Ltd. is a global pharmaceutical company based in India, engaged in providing affordable and innovative medicines. The company offers a wide portfolio of products and services, including pharmaceutical generics, active pharmaceutical ingredients, biosimilars, and differentiated formulations.
Therapeutic areas
Active pharmaceutical ingredients supplied
Substances Dr. Reddy's Laboratories Ltd. is evidenced to supply (US FDA Drug Master File or EU CEP). Open any ingredient to see its full supplier landscape, CAS number and patent status.
FDA compliance signals
50 FDA enforcement records linked to this company.
- recall — Class III2025-12-17
Sub potent drug: during the 9-month stability test conducted, the assay value for the affected lot was below specification limit.
- recall — Class II2025-10-15
Out-of-Specification (OOS) result during the 6-month stability testing; decreased preservative concentration.
- recall — Class II2025-07-23
Presence of foreign tablets/capsules: presence of foreign Divalproex Sodium Extended-Release 250mg tablet in a bottle of omeprazole capsules.
- recall — Class I2025-04-23
LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.
- recall — Class III2024-12-18
Failed Impurities/Degradation Specifications
- recall — Class III2024-11-27
Failed Tablet/Capsule Specifications
- recall — Class II2024-11-13
Failed Impurities/Degradation Specification
- recall — Class II2024-11-13
Failed Impurities/Degradation Specification
- recall — Class II2024-11-06
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
- recall — Class II2024-11-06
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
- recall — Class II2024-11-06
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
- recall — Class II2024-09-04
Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.
- recall — Class II2024-09-04
Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.
- recall — Class II2024-09-04
Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.
- recall — Class III2024-08-14
Labeling: Incorrect or Missing Lot and/or Exp Date. Missing lot number and expiration dates on packets
Is this Dr. Reddy's Laboratories Ltd.? Get in front of buyers actively sourcing.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Related companies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.